Check for updates

OPEN ACCESS

EDITED BY Natalia Szejko, Medical University of Warsaw, Poland

REVIEWED BY Michael Feldmeier, UCLA Health System, United States Courtney Gallen, University of California, San Francisco, United States Luigi Lavorgna, University of Campania Luigi Vanvitelli, Italy

*CORRESPONDENCE Min-Hyeon Park neominnie00@hanmail.net

SPECIALTY SECTION

This article was submitted to Digital Mental Health, a section of the journal Frontiers in Psychiatry

RECEIVED 05 July 2022 ACCEPTED 20 October 2022 PUBLISHED 29 November 2022

CITATION

Choi E, Yoon E-H and Park M-H (2022) Game-based digital therapeutics for children and adolescents: Their therapeutic effects on mental health problems, the sustainability of the therapeutic effects and the transfer of cognitive functions. *Front. Psychiatry* 13:986687. doi: 10.3389/fpsyt.2022.986687

COPYRIGHT

© 2022 Choi, Yoon and Park. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Game-based digital therapeutics for children and adolescents: Their therapeutic effects on mental health problems, the sustainability of the therapeutic effects and the transfer of cognitive functions

Eunhye Choi, Eun-Ha Yoon and Min-Hyeon Park*

Department of Psychiatry, Eunpyeong St. Mary's Hospital, Catholic University of Korea, Seoul, South Korea

Mental health problems in childhood and adolescence (e.g., attention deficits, problems in emotional understanding and subclinical levels of anxiety) are reported to develop further in adulthood and/or to increase the risk of developing mental health disorders in adulthood. Although it is important to provide treatment or prevention interventions for children and adolescents in order to reduce the risk of the further development of mental health problems, the pharmacological and behavioral treatments for this age group have limitations (e.g., limited access, unsustainable treatment effects and the lack of engagement in intervention). In order to overcome the limitations of conventional treatments, the use of digital technology, especially video games for this age group, is suggested. In order to be accepted as clinical interventions, objective evidence for the therapeutic effects of digital therapeutic that used video games to treat or prevent targeted mental health problems are required. Thus, this review aims to explore whether game-based digital therapeutics (DTx) for children and adolescents showed therapeutic effects on targeted mental health problems. As game-based DTx are suggested to show sustained therapeutic effects and the transfer of cognitive functions, it also reviews the maintenance of the therapeutic effects of DTx and the extent of the transfer of cognitive functions. Game-based DTx that are developed to treat or prevent mental health problems (e.g., attention deficit, depression) in children and adolescents are found to show therapeutic effects on targeted mental health problems despite the limitations (e.g., small sample size, limited investigation of the sustainability). This review would contribute to the understanding of whether there is objective evidence of the therapeutic effects of digital therapeutics using video games that deliver treatment or prevention interventions for mental health problems in children and adolescents.

KEYWORDS

children and adolescents, mental health problem, digital therapeutics, therapeutic effects, transfer, sustainability, video games

Introduction

More than 10% of children and adolescents in the world are reported to have mental health problems (1). With the improvement in diagnosis systems (2), there is an increase in the clinical diagnosis of neurodevelopmental disorders (e.g., attention deficits) in this age group compared to the past (3). An increased prevalence of affective disorders (e.g., depressive symptoms) in childhood and adolescence is also reported (3). Clinical or subclinical mental health problems (e.g., attention deficit, anxiety and depressive symptoms) in childhood and adolescence appear to be persistent into adulthood (4). About 50% of young adults show mental health disorders that are continued from their childhood psychiatric disorders (5). Moreover, children and adolescents, who report clinical or subclinical mental health conditions, are more likely to develop mental health problems later in their adulthood (6-8). As mental health problems in children and adolescents tend to be persistent and recurrent in their adulthood (9), it is important to provide effective interventions for mental health problems in this age group (10, 11).

However, a lot of children and adolescents are estimated to have difficulties receiving the interventions for their mental health problems (12) due to two barriers. One barrier is the side effects of pharmacological treatments that limit treatment options for this age group (13, 14). Pharmacological treatments that show side effects (e.g., headaches and insomnia) in some patients with attention deficits (13) are not acceptable for some children with attention deficits (15). In case of antidepressants, their safety and effectiveness in adolescents have been argued (16) despite the increased use of them in this age group (17). The other barrier is the limited access to the treatments (18). The number of adequately trained therapists or the availability of facilities is not sufficient to meet the needs for overall mental health problems (11, 19). In case of neurofeedback that aims to treat attention deficit hyperactivity disorder (ADHD), it offers visual or auditory reinforcement in order to alter activities of relevant brain regions (20, 21) that are found to show specific electroencephalography (EEG) patterns in children with ADHD (22). That is, as its treatment effects on ADHD is highly dependent on the ability of clinicians to establish links between the symptoms of a patient and his or her dysregulated EEG patterns in brain regions (20), the accessibility to the clinicians with the adequate level of trainings is required. Furthermore, the COVID-19 that results in social distancing and lockdown in some countries makes the access to face-to-face interventions even more limited (23). In order to successfully offer the interventions for mental health problems in children and adolescents by overcoming the barriers, it has become important to develop more innovative and cost-effective intervention methods for this age group (24).

Digital technology is suggested as a delivery tool for automated and self-directed interventions by improving the accessibility (25). Software-driven therapeutic interventions that aim to prevent, manage, or treat medical or chronic diseases are referred to as Digital Therapeutics (DTx) (26). Unlike wellness or other digital health products that deliver more personalized clinical care based on the understanding of healthrelated behaviors through digital technology (27, 28), DTx are developed to target a specific disorder or disease (29). DTx could target the conditions that are difficult to be intervened in frequently used interventions (30). As DTx are regarded as "an emerging class of medicines" (31), they also have obtained the approval of the relevant regulatory authorities (e.g., the U.S. Food and Drug Administration) (30) based on clinical evidence for the effectiveness similar to conventional medicines and medicine supplies (29). DTx that could decrease time demands of clinicians during the interventions (26) are found to be effective in the improvement of various clinical conditions (e.g., the impairment of sensorimotor functions, cognitive deficits and depression) by replacing or complementing other intervention methods (32). Among various technological platforms and systems that have been facilitated to enhance the delivery of healthcare services (26), video games (VGs) that can be helpful for mental health problems (e.g., emotion regulation, stress management, attention deficits and depression) are suggested as an attractive and immersive delivery tool for clinical interventions in children and adolescents (33, 34).

VGs, one of the most entertaining activities for children and adolescents (35), could provide them with more flexible and personalized learning environments (36) by maintaining the optimal level of challenges for players in response to their actions (37). Engagement issues and the limited consideration of individual differences in learning process are reported to limit the effective delivery of mental health interventions. For example, people with ADHD have difficulty managing their brain activities repeatedly over neurofeedback training sessions despite its effectiveness (20). The motivation level and the extent of engagement that children and adolescents show in cognitive trainings [e.g., Rational Emotive Behavior Education (REBE) interventions that focused on the cultivation of rational beliefs (11), cognitive behavioral therapy (CBT)] are also not stable during the intervention process (38, 39). That is, despite their effectiveness for anxiety symptoms (39), the way to deliver the interventions seems to be related to the decreased effectiveness (35, 40). Moreover, some children and adolescents (e.g., those with attention deficits) show difficulties learning new abilities in CBT that focuses on the shift of the anxious state trough relaxation trainings (37) and need more time to learn these skills (41). It is found to be difficult to consider the diversity of learning needs and individual differences in learning paces of children in the interventions (37).

Furthermore, the sustainability and generalization of therapeutic effects outside the intervention periods [e.g., (42)]

are concerns that should be considered in order to improve the effectiveness of the interventions for mental health problems. Pharmacological and behavioral treatments show unsustainable therapeutic effects over time (43, 44). Practice activities for the generalization of skills in CBT (e.g., role-playing and homework assignments) are not effective for various reasons (e.g., limited time and subjective boredom) (37) and learned skills in traditional biofeedback interventions show limited generalization in real-world settings despite their effectiveness on the reinforcement of emotional relaxation abilities (45). However, VGs could offer opportunities for the generalized practice of learned skills by making players feel a strong sense of agency, entertainment and rewards (37). Thus, implementing VGs or gaming elements (e.g., meaningful contexts and scenarios to serve learning objectives) (41, 46) in

the interventions for mental health problems of children and adolescents is suggested to have the potential to overcome the

limitations of frequently used mental health interventions. Taken together, despite the increasing needs for mental health interventions in children and adolescents, intervention options for this age group are limited and effective interventions report concerns that could influence the effectiveness during and after the interventions. The implementation of digital technology is suggested as alternative treatment or prevention interventions for mental health problems (23). Among various options of digital technology, VGs are found to be cost-effective (37) and age-appropriate (33, 34) delivery tool for children and adolescents with mental health problems. Although DTx using VGs are suggested to have the potential to treat or prevent mental health problems in children and adolescents by overcoming concerned issues of frequently used interventions, the objective evidence for the effectiveness of DTx is not sufficient (47). The safety and efficacy of DTx should be proved for the acceptance for DTx by patients and clinicians (48), and some game-based DTx do not show sustained interventions effects (32) despite the potential for the generalization of skills that are learned in interventions (37, 41). Thus, this study aims to review whether game-based DTx show therapeutic or preventive effects on targeted mental health problems in children and adolescents. It also reviews the sustainability of the therapeutic effects of game-based DTx. Moreover, the extent of transfer of cognitive functions in game-based DTx for children and adolescents is reviewed. Not only intervention outcomes (e.g., decreased risk of falls) but also cognitive functions (e.g., processing speed and selective attention) were improved in older individuals (e.g., those who aged more than 60 years) who received game-based trainings (49-52). Improved cognitive functions after the game-based training (i.e., NeuroRacer) were comparable to cognitive functions of 20-yearolds and were maintained for 6 months along with alterations in brain activation (53). The results of studies in the nonclinical population suggested that implementing VGs has the potential for neuroplasticity. However, playing VGs are found

to be related to near transfer of cognitive functions [i.e., the improvement of cognitive functions (e.g., attention) that are related to characteristics of VGs] (54, 55). That is, the VG-related neuroplasticity is limited to the brain regions that are related to characteristics of VGs. As the VG-related neuroplasticity could influence the therapeutic effects of DTx, the transfer of cognitive functions in children and adolescents with subclinical or clinical levels of mental health problems after game-based DTx interventions is additionally reviewed.

Methods

Literatures search was conducted in databases (e.g., PubMed and Web of Science) and Google Scholar with search terms (e.g., "digital therapeutics", "video game digital therapeutics", "digital therapeutics for children and adolescents", and "gamebased digital therapeutics for children and adolescents") without the restriction of the publication date. In the process of screening searched literatures, not only the age of children and adolescents but also the measurements for therapeutic effects of DTx were not limited. Although DTx usually get approval from the regulatory institutions (30), game-based DTx for mental health problems in children and adolescents are an emerging research field where only one game-based DTx (i.e., EndeavorRx) for this age group was identified to be FDA-approved (56). Thus, game-based DTx in this study is defined as interventions that use VGs as a delivery tool to treat or prevent targeted mental health problems in children and adolescents with or without the approval from regulatory authorities. Mental health problems in the review encompass both neurodevelopmental and affective disorders that show an increasing trend in childhood and adolescence (3). Through the process of screening the searched literatures, seven game-based DTx for this age group were identified. In order to explore all relevant literatures that examined therapeutic or preventive effects of identified DTx, the additional search of literatures was conducted by using names of DTx that were indicated in literatures (e.g., "Project:EVO" and "RAGE-Control") as additional search terms. After the additional search, abstracts were screened to identify whether children and/or adolescents were included as participants and whether the therapeutic effects of identified DTx were examined. The inclusion criteria of the literatures in this review were (1) full-text original research articles published in English and (2) the examination of therapeutic or preventive effects of gamebased DTx that aimed to target mental health problems in children and adolescents. That is, DTx that are not developed to target mental health problems in children and adolescents and that do not include gaming elements as a delivery tool were not included. Research articles that did not investigate therapeutic or preventive effects of identified DTx in children and/or adolescents were also excluded. As a result, 22 research articles that met the inclusion criteria were included in this review.

Name of DTx

Therapeutic effects of DTx for children and adolescents

Using digital devices is suggested to have the potential for the rehabilitation of cognitive functions by enhancing the neuroplasticity (32). Based on the potential effectiveness of game-based DTx for the cognitive rehabilitation (32), there are game-based DTx that are developed for children with ADHD or autism spectrum disorder (ASD) who show

TABLE 1 The explanation of seven DTx for children and adolescents.

Explanation

The focus of

impairments in attention function and inhibitory control (44, 57). Children and adolescents are reported to have not only neurodevelopmental disorders but also affective disorders (3). Some children and adolescents report difficulties regarding emotional understanding that is related to the further development of emotional disorders (11). Some of them report subclinical levels of anxiety or depression (37, 58). That is, there are also game-based DTx that aim to treat or prevent affective disorders in children and adolescents. That is, seven

Name of D1x	the intervention	
EndeavorRx	attention	EndeavorRx, which is referred as "Project: EVO" or "AKL-T01" in literatures, is developed by Akili Interactive based on
		the <i>Neuroracer</i> model (42, 60). In order to treat children with attentional deficits (age range = 8–12 years), it uses gaming
		elements (e.g., action VG graphics, and real-time adaptive mechanisms) (42, 44, 61). It is approved by the FDA as the first
		DTx that delivered the treatment by using VG and is prescribed for children with ADHD (56). The children are asked to
		play it for 25 minutes daily on five days of a week during the prescribed period (i.e., 4 weeks) (44, 61).
ATENTIVmynd	attention	ATENTIVmynd, which is referred as 'Brain-computer Interface' in literatures, is developed by Neurosky Inc (4). It
		deploys an EEG-headband that is used to calibrate the optimal state of attention and to track attention states during the
		game play (20) with the training game, CogoLand, where children navigate the environment by controlling an avatar (4) .
		The speed of the avatar's movement is modulated by the level of their concentration (4). The training consists of about 24
		sessions between 6 and 8 weeks and each game takes about 20-25 min for children to play through an end (62).
RECOGNeyes	attention	RECOGNeyes is developed by University of Nottingham. Players learn the way to control different aspects of visual
		attention by using their eyes as a game controller (63).
REThink	emotion regulation	REThink is a standalone application that is adapted to be used in tablets as a prevention tool in children and adolescents
		from the general population (59). It helps them to build psychological resilience by including main character, RETMAN,
		who supports the learning of healthy strategies to cope with dysfunctional negative emotions (e.g., anxiety and anger)
		(11, 59). Based on the principles of REBT and REBE interventions, REThink consists of seven levels with specific
		objectives (e.g., "identifying emotional reactions", "identifying cognitive processes", and "building relaxation skills") (11).
Mightier	emotion regulation	Mightier, which is referred as RAGE Control in literatures, is developed in Boston Children's hospital and Harvard
		Medical School (64). In order to improve emotion regulation skills in children and adolescents, it uses biofeedback and the
		relaxation in the modified VG design inspired by a classic VG, Space invader (45, 65, 66). That is, its storyline is to defend
		the attack of aliens as a hero by controlling a space ship and firing spaceships of aliens (65). During the game playing, their emotional arousal (i.e., heart rate) is taken as an input (45) that moderates the activity of firing a bullet (65). With the
		progress in the game, "friendly spaceships", which is an additional challenge for inhibitory control, are introduced (65).
MindLight	anxiety	It is developed by Play Nice Institute and Gain Play studio (67). It deploys three evidence-based strategies for the
0	,	reduction of anxiety in children and adolescents (age range: 8–16 years): (1) neurofeedback training (i.e., the guidance to
		keep their EEG waves consistent throughout the play), (2) exposure training (i.e., a validated CBT treatment component
		for children to practice various relaxation techniques) and (3) attention bias modification (i.e., modified attentional
		system to attend more to positive stimuli) (37). Its storyline is to save a grandmother from evil forces by exploring her
		dark mansion, chasing away or uncovering "fear events" and solving problems (68). In the exploration process that
		provokes the anxiety, children use their MindLight of which brightness is associated with the real-time relaxation state
		measured by the EEG headset (68).
SPARX	depression	SPARX is an interactive fantasy game that is developed for adolescents with depression (8, 58). The adolescents choose,
	I	customize and control their avatars in order to go through seven challenges, related to CBT components (e.g., relaxation
		training, social skills and cognitive restructuring) (69), for the completion of the mission (i.e., the removal of the world of
		gloom and negativity) (58, 70).
		Boon and the Burney (1, 60, 10).

REBT stands for Rational Emotive behavioral Therapy, RAGE Control stands for Regulate And Gain Emotional Control, SPARX stands for Smart, Positive, Active, Realistic, X-Factor Thoughts.

game-based DTx that were identified through the literature search in databases are found to target attention deficits, emotional regulation, anxiety or depressive symptoms in this age group (see Table 1). While REThink aims to offer prevention intervention by making children and adolescents learn emotion regulation skills (59), other six game-based DTx aim to offer treatment interventions for targeted mental health problems.

EndeavorRx

Children with ADHD showed a high level of adherence when playing EndeavorRx (42, 44, 57). EndeavorRx that was feasible in home environments and acceptable in the children (42, 57, 60) was found to significantly improve attention function in not only children with attention deficits (44, 71) but also those without the deficits (42, 60). Children, who had ASD and ADHD, also showed a trend of the improved attention function and inhibitory control (57). That is, based on parental reports, the effectiveness of EndeavorRx on decreased ADHD symptoms was found in children who had ASD and ADHD (57), children who had a recent history of pharmacological interventions for ADHD (44), and children who had ADHD without other comorbidities (71). The intervention-related improvement in attention functioning was found to be affected not by the changes in basic motoric speed but by the intervention (60, 71). Moreover, the extent of improvement in attention function through the EndeavorRx intervention was greater in children with a higher level of attention deficits (42, 60) and the improvement of attention resulted from the movement of more children, who received the intervention, into the normative ranges of attention function (44). Both one third of children who had sensory processing dysfunction (SPD) and inattentive-ADHD (60) and 44% of children who had ADHD without other comorbidities (71) did not meet the clinical threshold for inattention after the intervention. Their performance regarding attention after the intervention was comparable or even better than the baseline attention performance of typically developing children (60). Furthermore, as parental reports of reduced inattentive behaviors were associated with significantly increased middle frontal theta (MFT) activity power (60), playing EndeavorRx was related to the changes in the activations of brain regions for attention function (60, 71). Unlike the significant increases in MFT in the middle of the attention task in children with SPD and inattentive-ADHD (60), the significant increases in MFT in children who had ADHD without other comorbidities were found in the earlier and later stages of the task (71). These results suggest the therapeutic effects of EndeavorRx on attention deficits in children.

ATENTIVmynd

With a high level of compliance with ATENTIVmynd in children (4), children with ADHD showed significant decreases

in inattentive symptoms after playing ATENTIVmynd (4, 72). Both parents and clinicians reported the improvement in ADHD symptoms in children through ATENTIVmynd compared to non-pharmaceutical interventions (20). Parental reports also showed the significant improvement of hyperactive-impulsive symptoms in children with the combined subtype of ADHD (4). Children with more severe attention deficits showed greater effects of ATENTIVmynd intervention (4). Moreover, children with ADHD showed the reorganization of the functional networks (e.g., decreased functional connectivity within the salience network), which was associated with the improvement of inattentive symptoms and the reduction of internalizing problems (72). ATENTIVmynd showed therapeutic effects of targeted attention deficits in children.

RECOGNeyes

Not adolescents but the majority of children, who were younger than 12 years, reported that playing RECOGNeyes was enjoyable and its levels of challenges were appropriate for them (63). While playing RECOGNeyes did not result in the change in the number of errors (i.e., commissions and omissions), the children and adolescents, who played RECOGNeyes by using their eyes as a controller, showed decreases in the level of impulsivity, made fewer fixations and fixated on the target for a longer duration than those who played RECOGNeyes by using the mouse as a controller (63). They also showed the improvement of impulsivity (63). That is, RECOGNeyes was found to improve the control of attention in children and adolescents with ADHD (63).

REThink

Compared to children who received REBE intervention, children, who played REThink, reported a higher level of satisfaction in the middle of REThik intervention that was an important factor to booster the therapeutic effects (11). Playing REThink was found not only to reduce overall negative emotional symptoms (e.g., anger and anxiety) but also to improve the emotional awareness and emotional control (11). That is, the risk of the development of problems decreased in children, who played REThink, but not in children, who received REBE intervention, and those in the waitlist group (11). Moreover, despite the overall decreases in anxiety symptoms in all groups of children, children, who played REThink, showed more inhibited activation in the frontal brain regions of the right hemisphere that was associated with negative affects and the motivation to withdraw (24). That is, it was found that the effectiveness of REThink on emotion regulation was associated with changes in irrational beliefs (73). The reports of emotional symptoms and depressive moods decreased in children, who played REThink, compared to those who received

Mightier

Mightier that was rated as a highly satisfactory, enjoyable and helpful intervention approach with a high level of adherence was found to be an acceptable intervention approach in children (66, 74). A case study that showed the feasibility of Mightier for the engagement and its effectiveness in coaching selfregulation skills suggested the potential that Mightier would have therapeutic effects in children and adolescents with anger and aggression (74). Compared to anger control therapy (ACT) that aimed to treat anger and aggression as one of CBT programs (75), Mightier that augmented ACT was found to significantly decrease symptoms of emotional arousal (e.g., anger) and to improve the maintenance of calm states in children and adolescents (66). As ACT did not show therapeutic effects on emotional arousal and the control of emotion (66), Mightier appeared to have the potential to be used as a standalone intervention for the emotion regulation. Moreover, as children whose primary diagnosis was a restrictive eating disorder showed improvement in anger after playing Mightier, Mightier appeared to have valuable therapeutic effects in children who showed some emotional problems regarding anger in addition to their primary mental health problems (66).

MindLight

MindLight that was rated to produce a higher level of anxiety by children compared to the commercial control game was reported to be less appealing than the control game (37) but more equally appealing like CBT interventions (76). The effectiveness of MindLight on the reduction of anxiety symptoms in children with the subclinical level of anxiety was found to be comparable to that of commercial control games (e.g., "Max" where players control the avatar in puzzle platform VG) (37, 77). Although children, who played MindLight, showed the similar extent of improvement of anxiety symptoms compared to those who played control games immediately after the intervention (37), not only children with more severe level of anxiety but also children with ASD in addition to subclinical anxiety symptoms showed improved anxiety symptoms after playing MindLight (37, 77). The therapeutic effect of MindLight on anxiety symptoms in children with elevated levels of anxiety was also comparable to that of CBT (76). MindLight was found to be an effective intervention for anxiety without the further addition of CBT elements in that including more CBTrelated components in MindLight for children with ASD did not have additional therapeutic effects on anxiety (78). Moreover, compared to boys, girls, who showed higher levels of anxiety

symptoms at the beginning of the intervention, showed greater decreases in their anxiety symptoms after playing MindLight (76). These results suggested that MindLight that provided the engaging context for children to practice their strategies for emotion regulation (37) showed the therapeutic effect on the subclinical level of anxiety that was comparable to the game- or CBT-relevant improvements (37, 76, 77).

SPARX

SPARX that was reported as a helpful and satisfactory intervention (8, 58) showed a high level of adherence in adolescents (58, 79) despite the relatively low adherence levels in the adolescent sample including transgender adolescents (69). The effectiveness of SPARX in the reduction of depressive symptoms was comparable to that of CBT in Dutch female adolescents with elevated depressive symptoms (8). Compared to usual treatments (e.g., counseling), SPARX was found to significantly reduce depressive symptoms in adolescents with mild to moderate depressive disorder (58) and adolescents who were excluded from mainstream education (79). The therapeutic effect of SPARX on depressive symptoms was greater in adolescents who showed more severe level of depression at the beginning of the intervention (58). However, SPARX did not show the improvement of depressive symptoms in transgender adolescents (69). Although SPARX did not effectively reduce depressive symptoms in some adolescents, it was suggested to have the therapeutic effect on depressive symptoms that was comparable to or better than the interventions for depression.

The identified seven game-based DTx are as effective as usual treatments (e.g., CBT) or show better therapeutic or preventive effects compared to some interventions (e.g., REBE interventions) (see Table 2). EndeavorRx, ATENTIVmynd and RECOGNeyes that target attention deficits show therapeutic effects in children and adolescents with ADHD (4, 44, 57, 63, 72). REThink and Mightier result in decreased symptoms of negative emotions (e.g., anger and depression) and improve emotional control compared to frequently used interventions (e.g., REBE interventions) (11, 24, 66, 73). While the therapeutic effect of MindLight on anxiety in children and adolescents is comparable to commercial VGs (37, 77) or CBT (76, 78), the extent of improvement of depression is found to be greater in adolescents who play SPARX than those who receive frequently used treatments (e.g., counseling) (58) and to be comparable to that of the CBT-based prevention approach (8).

The sustainability of therapeutic effects of DTx

Therapeutic effects of DTx were found to be sustained at follow-ups. The treatment effects of ATENTIVmynd, MindLight and SPARX on targeted mental health problems in children

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
Anguera et al. (60)	1. Children with SPD +	Behavioral measures	9 months	Behavioral changes in cognitive control	- The lack of power for the dissociation
EndeavorRx	IA ($N_{Experiment1} = 20$,	- Perceptual		- Improved performance in the	of attention-based improvements on
	$N_{female} = 8$, $M_{age} =$	discrimination paradigm		perceptual discrimination in children	behavioral measures
	$9.7\pm1.3; N_{Experiment2}$			with SPD+IA and typically developing	- The lack of SPD placebo control group
	= 20, N _{finalsample} $=$	- TOVA		children	
	17).	- EVO assessment (i.e.,		- Improved performance in the TOVA	
	2. Age- and	perceptual		in all groups	
	gender-matched	discrimination,		- Improved reaction time in EVO	
	children with SPD	visuomotor tracking and		assessments in all groups	
	$(N_{Experiment1} = 17,$	multitasking ability)		- No group difference in basic response	
	$N_{female} = 8; M_{age} =$	- Parent report measure		time task	
	$10.3 \pm 1.5;$	Vanderbilt ADHD		Parent report of attention	
	$N_{Experiment2} = 13$,	Diagnostic Parent		- Significantly reduced inattention	
	$N_{\text{finalsample}} = 10$).	Rating Scale		behaviors in children with SPD+IA after	
	3. Typically developing	Neural assessment		the training and at 9-month follow-up	
	children (N _{Experiment1}	- EEG		Neural assessment	
	= 25, N _{female} $= 12$,	Additional measure for		- Significantly increased MFT power in	
	$M_{age}=10.5\pm1.3;$	confounding variables		children with SPD+IA	
	$N_{Experiment2} = 24$,	- Basic response		- A correlation between the	
	$N_{\text{finalsample}} = 22$).	time task		improvement of MFT power and	
				decreased parental reports of	
				inattentive behaviors	
Davis et al. (42)	Children who were aged	Safety and feasibility	No follow-up	Safety and feasibility	- The necessity of additional measures
EndeavorRx	between 8-12 years and	measures		- The completion of 84% of prescribed	for the translation of cognitive
	whose functioning was	- Parental reports of		in-home sessions across all participants	improvement to everyday functioning
	within the normal range	adverse events		- Reports of 9 adverse events that were	- The plausible influence of parent
	of	- Compliance		not related to EVO over all study phases	expectations for the intervention
	intellectual functioning				treatment effects on the observed

10.3389/fpsyt.2022.986687

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	1. Children with ADHD	- Questionnaire on		-6.9 of enjoyment rating for EVO on a	improvement in parent reports
	$(N = 40, N_{female} = 16;$	intervention appeal		1-10 scale	- The limited generalizability of the
	$M_{age} = 10.3$	Measures for attention		Attention functioning	findings to the entire general populatio
	\pm 1.2) 1–2. ADHD	and other cognitive		- Significantly improved performance in	of children with ADHD
	high severity	functions		API of the TOVA in children with	- Concern for Type 1 error for some
	subgroup($N = 22$,	- TOVA		ADHD and a greater intervention effect	results despite the Bonferroni correction
	N _{female} = 8; M _{age} =	- BRIEF-Parent Form		in ADHD high severity subgroup	for significant values
	$10.2 \pm 1.2)$	CANTAB		- Significant improvements on	
	2. Age-matched			indicators of ADHD severity (i.e.,	
	typically developing			Reaction Time Mean Standard Score	
	children ($N = 44$,			and Reaction Time Variability Standard	
	$N_{female} = 19, M_{age} =$			Score) only in the ADHD high	
	10.5 ± 1.4 ; N _{finalsample}			severity subgroup	
	= 40)			Cognitive functioning	
				- Improved spatial WM in children with	
				ADHD and the improvement in rapid	
				visual processing and delayed match to	
				sample in typically developing children	
				- Non-significant improvement of WM	
				in children with ADHD and the	
				significant improvement of WM and	
				inhibition in the ADHD high severity	
				subgroup	
				- No changes in summary scores of	
				BRIEF (i.e., metacognition,	
				behavioral regulation, global executive	
				composite) over time in	
				all groups	
erys et al. (57)	Children with ASD and	Measures of attention	No follow-up	Feasibility and acceptability	-The use of control treatment conditio
ndeavorRx	ADHD ($N_{screened} = 42$,	and cognitive functions			that completely differed from the
	age range = $9-15$ years;				experimental condition

80

60

TABLE 2 (Continued)

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	$N_{eligible} = 19$, $N_{female} = 2$,	Primary outcome		-A high level of adherence to the	-The plausible influence of parent
	age range = $9-13$ years,	measure: TOVA		treatment protocol in both groups and	perception of engagement on the paren
	$M_{age} = 11.25 \pm 1.44)$	- ADHD-RS-IV: Home		no withdrawal of children from the	ratings that were conducted after the
	1. Multi-tasking	- BRIEF, 2 nd edition		study	treatment
	treatment group (N =	- CANTAB		- Positive reports for the benefits of the	- The exclusion of a large percentage of
	11)	- SSIS		intervention in both children	children with ADHD at the screening
	2. Alternative			and adolescents	stage
	educational treatment			Preliminary Efficacy	- Some concerns of the extent to which
	group $(N = 8)$			- Non-significant but improved	TOVA measures cognitive interference
				performance in the TOVA API in the	
				multi-tasking treatment group and	
				non-significant but overall worsening in	
				the TOVA API in the alternative	
				educational treatment group	
				- Significant reductions in	
				ADHD-RS-IV, BRIEF-2, SSIS problem	
				behaviors in the multi-tasking treatment	
				group but non-significant reductions in	
				ADHD-RS-IV, BRIEF-2 and SSIS	
				problem behavior scores in the	
				alternative educational group	
				- No significant gains in CANTAB's	
				spatial WM and SSIS Social skills in	
				both groups	
Kollins et al. (44)	Children with ADHD	Primary outcome	No follow-up	Feasibility	-The exclusion of a substantial number
EndeavorRx	$(N_{screened} = 857, N_{eligible})$	measure		- No parent reports of serious adverse	of children with ADHD due to the
	= 348, age range:	- The mean change		events related to the intervention but	criteria for attention deficit
	8-12 years)	in TOVA		some reports of frustration (3%) and	- The limited generalizability of finding
		Secondary outcome		headache (2%) in AKL-T01 group	to the broader populations of children
		measure			with ADHD with comorbid condition
					or taking medication for ADHD

10.3389/fpsyt.2022.986687

TABLE 2	(Continued)
---------	-------------

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	1. AKL-T01 group (<i>N</i> =	-IRS		-No dropout in both groups due to	-Concerns for the beneficial effects o
	180, $N_{female} = 55$, age	- ADHD-RS-IV		adverse events	the intervention on attention in
	$= 9.7 \pm 1.3;$	- CGI-I		Primary outcome	different intervention periods or afte
	$N_{\text{finalsample}} = 169)$	- BRIEF		- Significant improvement in TOVA API	the intervention period
	2. Control group ($N =$			score in AKL-T01 group but not in	- No power calculations for secondar
	168, $N_{female} = 45$, age			control group	outcomes or post-hoc analyses
	$= 9.6 \pm 1.3;$			- The greater improvement in the TOVA	- No collection of mechanistic data
	$N_{\text{finalsample}} = 160)$			API in the AKL-T01 G compared to the	(e.g., EEG)
				control group with the movement of	
				more children with ADHD into the	
				normative ranges of attention	
				functioning after the intervention	
				Secondary outcomes	
				- Significant improvement in all	
				secondary measures but no group	
				differences in secondary measures (i.e.,	
				IRS, ADHD-RS, ADHD-RS-I,	
				ADHD-RS-H, BRIEF-Parent Inhibit and	
				Working Memory and Metacognition)	
				- Significantly higher parental-reported	
				improvement of attention in the	
				AKL-T01 G	
				- Significant effects on ADHD-RS,	
				ADHD-RS-I and CGI-I in children who	
				discontinued stimulant medication for	
				AKL-T01 intervention	
Gallen et al. (71)	28 children with ADHD	Primary measure	No follow-up	Neural assessment outcome	-No placebo control group for the
EndeavorRx	$(N_{\text{finalsample}} = 25,$		-		comparison

Choi et al.

10

TABLE 2	(Continued)
---------	-------------

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	$N_{male} = 20, M_{age=} 10.44$	-Neural assessment: EEG		-Increased MFT activities at the early	-Concerns for the persistency of the
	\pm 1.23, age range: 8–12)	recording during a		and later stages of a go/no-go task but	neural effects and the uncertainty in th
		perceptual		non-significant increases in MFT	relationship of the neural effects with
		discrimination task (i.e.,		activities in the peak time of the task	aforementioned behavioral measures
		go/no-go task)		Behavioral assessment outcomes	attention
		Behavioral measures		- Significantly improved reaction time	- No correction for multiple
		- Perceptual		in perceptual discrimination task after	comparisons in the reported association
		discrimination task		the intervention	between neural and behavioral gains
		- Sustained attention task		- No improvement in reaction time or	- The necessity of the replication of a
		(i.e., visual continuous		reaction time variability in sustained	lager sample of the heterogeneous
		performance task)		attention task but the improvement in	ADHD population
		Parent-report measure		attention lapses	
		- Vanderbilt ADHD		- No relation of basic response time	
		diagnostic parent scale		changes with intervention-related	
				improvements in behavioral outcomes	
				Parent-reports	
				- Significant decreases in	
				parent-reported ADHD	
				inattention symptoms	
				Relationship between neural and	
				behavioral assessments	
				- A significant relation of MFT-changes	
				in early and post stages with the	
				improvement of attention lapses in the	
				sustained attention task	
Lim et al. (4)	Children who were	Neural measure	3 months with three	Adherence	-The possibility of the exaggeration o
ATENTIVmynd	diagnosed to have		once-monthly booster		the treatment effect due to uncontroll
	~		training sessions		open-label design of the study

(Continued)

10.3389/fpsyt.2022.986687

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	ADHD without the	D.4.017			
	experience of stimulant	- BASM		- The completion of the study in 85%	
	medication treatment	Outcome measure		participants (N=17)	
	$(N_{enrolled} = 25; N_{eligible} =$	- ADHD-RS completed		Neural outcome	
	20, $N_{female} = 4$, age	by parents		- Non-significant but increasing trend in	
	range: 6–12 years, M _{age}			the mean BASM scores (i.e., the	
	$= 7.8 \pm 1.4$).			improvement of inattentive symptoms)	
	- children with the			in Week 20 (i.e., the post-boosters	
	combined subtype of			period) compared to in Week 0	
	ADHD ($N = 14$).			(i.e., baseline)	
	- children with			Behavioral outcomes	
	inattentive subtype of			Significant decreases in inattentive	
	ADHD $(N = 6)$.			symptoms, hyperactive impulsive and	
				combined symptoms immediately after	
				the intervention	
				- No significant further improvement in	
				inattentive or hyperactive-impulsive	
				symptoms of ADHD by receiving	
				monthly booster trainings for 3	
				consecutive months after the	
				intervention but sustained intervention	
				effect at 24 weeks	
				- Greater improvements in attention in	
				children with more severe inattentive,	
				hyperactive-impulsive and combined	
				symptoms immediately after	
				the intervention	
Qian et al. (72)	Boys with ADHD (either	Neuropsychological	No follow-up	Neuropsychological outcomes	-A relatively small sample size after
ATENTIVmynd	combined or	measures			removing poor-quality data that
	inattentive subtypes)				resulted from the excessive motion

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	 Intervention group (N = 44, N_{finalsample} = 18, M_{age} = 9.00± 1.50) Control group (N = 22, N_{finalsample} = 11, M_{age} = 9.45± 1.29) 	-ADHD-RS - CBCL Neural measure - rs-fMRI and structural MRI		 Significantly greater reduction in inattention scores of the ADHD-RS in the intervention group compared to the control group Non-significant but slightly greater reduction in CBCL internalizing problems in the intervention group than in the control group Neural outcome A trend of increased functional connectivity within and between relevant networks (e.g., salience/ventral attention network, dorsal attention networks) only in control group over time Significant reductions in nodal degree and clustering coefficient but significantly increased nodal closeness in salience/ventral attention network, executive control network and default mode network after the intervention The correlation of changes in functional networks (i.e., less increased functional connectivity in the intra-salience/ventral attention network and the inter-network between salience/ventral and dorsal attention networks and reduced local functional processing in relevant brain regions) after the intervention with the 	-The possibility of further correction of physiological noise in the fMRI datase through the implementation of advanced fMRI preprocessing techniques ADHD subtypes that were not distinguished due to relatively small sample size - The necessity of further studies with longer duration of the intervention and follow-ups

Choi et al.

13

10.3389/fpsyt.2022.986687

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
				improved inattention symptom and	
				internalizing problems in children	
				with ADHD	
McDermott et al.	46 children with ADHD	Behavioral measures	3 months	Behavioral outcomes	-Potential expectation bias of clinicians
(20)	$(N_{female} = 14; age range$	- ADHD-RS completed		- Significant decreases in both	and parents on the intervention effect
ATENTIVmynd	= 8–12 years, M_{age} =	by clinicians		ADHD-RS mean scores and mean score	due to non-blind group assignment
	$9.57 \pm 1.34)$	- CGI-I		of CGI in the intervention group	- No comparison of the intervention
	1. Intervention group	- Quotient [®]		- Worsening performances of the	against one evidence-based treatment
	(N = 21)	ADHD system		intervention group in $Quotient^{\mathbb{R}}$	due to various options of treatments,
	2. Waitlist group	Academic measures		ADHD system which was found to be	including no treatment, that were given
	(N = 19)	- PERMP		not correlated with behavioral reports or	to the control group
	*Children who	- WJ-III		training-related improvements	- No comparison group at the follow-up
	dropped during the			- The maintenance of	- Limited generalizability of the findings
	training or wait			intervention-related improvements at	due to relatively small sample size
	period ($N = 6$)			the follow-up	
				Academic outcomes	
				- Significantly improved performance in	
				the PERMP in the intervention group	
				compared to waitlist group	
				- A trend of improved performance in	
				WJ-III understanding directions (i.e.,	
				the ability to control their impulses and	
				follow directions) in the intervention	
				group but no group differences in	
				Reading fluency and Math fluency	
García-Baos et al.	28 Children and	Acceptability measure	No follow-up	Acceptability outcome	- Some group differences in the number
(63)	adolescents with ADHD	- A usability and		- Reports of appropriateness of difficulty	and duration of fixations in the short
RECOGNeyes	(including 7 children	enjoyability questionnaire		level and enjoyment in the majority of	word task at the baseline
	with comorbid dyslexia			children who were younger than	- The necessity for a longer period of
	and 2 children with a			12 years	intervention with a larger sample size

Choi et al.

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	learning disability; N _{boy}	Behavioral measures		Behavioral outcomes	
	= 18, age range:	- frog task (i.e.,		- Significantly decreased impulsivity	
	8-15 years)	probability of ADHD,		score in the RECOGNeyes group after	
	1. RECOGNeyes group	severity of ADHD,		the intervention	
	2. Age-matched control	hyperactivity index,		- Significantly decreased reaction time	
	group using mouse to	impulsivity index)		for attention, increased durations of	
	play the game	- word recognition task		fixations and decreased number of	
		(i.e., dyslexia index,		fixations in attention assessment tasks in	
		performance parameters)		the RECOGNeyes group after	
				the intervention	
David et al. (11)	Children and adolescents	Acceptability measure	No follow-up	Acceptability outcome	The possibility of the lack of significant
REThink	$(N = 165, N_{\text{finalsample}} =$	- TS-VAS		- Significant difference in satisfaction	results for REBE intervention due to the
	142, $N_{female} = 91$; age	Primary measures		between REThink and REBE group in	delivery of the intervention in schools
	range: 10-16 years)	- SDQ—child version		the middle of the intervention but	- The necessity for the follow-up
	1. REThink group ($N =$	- The subscale of		no-significant group difference in the	- Validation issues of some measures
	48; $M_{age} = 13.0 \pm 2.0)$	depressive moods		satisfaction after the intervention	(e.g., FD-CMS)
	2. REBE group ($N = 48$;	from EATQ-R		Primary outcomes	
	$\mathrm{M}_{\mathrm{age}} = 12.7 \pm 1.9)$	Secondary measures		- Significantly decreased scores of SDQ	
	3. Waitlist group ($N =$	- ERICA		emotional symptoms and EATQ-R	
	46; $M_{age} = 12.9 \pm 2.2$)	- Other three subscales		depressive mood	
		(i.e., attention, fear,		Secondary outcomes	
		inhibitory control) of		- Significantly increased ERICA	
		EATQ-R		awareness in the REThink group	
		- FD-CMS—girls and		- Significantly increased scores of	
		boys versions		EATQ-R attention and ERICA control	
				in the REThink group and the REBE	
				group	
				- Marginally significant group difference	

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
David et al. (73)	Children and adolescents	Primary measures	No follow-up	- No change in CASI total score in the	- The usage of standard assessment
REThink	($N = 165$, N _{finalsample} =	- SDQ—child version		waitlist group and marginal,	points
	142, $N_{female} = 91$; age	- EATQ-R		non-significant change in CASI total	-The delivery of interventions in school
	range: 10-16 years)	Measures for		score in the REBE group but	and children's previous exposure to suc
	1. REThink group ($N =$	hypothesized mediating		significantly decreased CASI total score	intervention programs
	48, $N_{female} = 36$; M_{age}	variables		in the REThink group	
	$= 13.0 \pm 2.0)$	- CASI		-The significant association of changes	
	2. REBE group ($N = 48$,	- CATS-N/P		in CASI total score with SDQ emotional	
	$N_{female} = 31; M_{age} =$			symptoms and EATQ-R depressive	
	12.7 ±1.9)			symptoms in the REThink group	
	3. Waitlist group ($N =$			-The prediction of group contrast (i.e.,	
	46, $N_{female} = 22$; M_{age}			the REThink group or the waitlist	
	$= 13.0 \pm 2.2)$			group) for changes in CASI total scores,	
				SDQ emotional symptoms and EATQ-R	
				depressive mood	
				-No difference in the intervention	
				efficacy depending on the age or gender	
David et al. (24)	Children and adolescents	Report measures	No follow-up	Report outcome	- The limited generalizability of this
REThink	$(N = 165, N_{\text{finalsample}} =$	-'concern and anxiety'		- Significant decreases in state anxiety in	findings based on a convenience sampl
	134; age range:	subscale of PAD		all groups after the intervention	- The dropout of participants that
	10-15 years)	Neural measures		Neural outcome	resulted from the inherent limitation o
	REThink G ($N = 47$,	- EEG data of frontal		- Increased frontal alpha asymmetry	the used equipment
	$N_{female} = 34; M_{age} =$	brain regions during the		scores in the REThink group after the	- No validation of the anxiety subscale
	$13.04 \pm 2.07)$	impromptu speech task		intervention	of the PAD in children and adolescent
	REBE G ($N = 42$, N _{female}			- Significant negative relationship	samples
	$= 23; M_{age} = 12.81$			between frontal alpha asymmetry and	- The lack of control on the
	± 1.92)			state anxiety after the	metacogntion for children and
	Waitlist G ($N = 45$,			REThink intervention	adolescents in the subjective measure
	$N_{female} = 21; M_{age} =$				
	$12.96 \pm 2.17)$				

Choi et al.

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
Ducharme et al.	Children and adolescents	Acceptability measure	No follow-up	Acceptability outcome	- The small sample size
66)	who did not show the	- The therapeutic		- A high level of satisfaction and	- The use of not a randomized control
Mightier	improvement in the	helpfulness questionnaire		helpfulness with the treatment in the	but a historic control group and the lack
	anger control with			intervention group	of cultural diversity of the experimental
	treatment as usual (age	Behavioral measure		Behavioral outcome	group
	range: 9–17 years)	- STAXI-CA		- Significantly decreased scores of	- No inclusion of objective measures for
	1. Intervention group	Physiological measure		STAXI-CA subscales (i.e., state anger,	anger or aggression
	that had received	- Heart Rate		trait anger and anger expression-out)	
	anger control therapy	- The therapeutic		and marginally decreased scores of	
	with mightier ($N =$	helpfulness questionnaire		anger expression-in subscale in the	
	20, $N_{\text{finalsample}} = 18$,			intervention group	
	$N_{female} = 13; M_{age} =$			Physiological outcome	
	$13.7 \pm 2.1)$			- Significantly improved ability to	
	2. Treatment as usual			maintain their heart rate in the	
	group that had			intervention group	
	received anger control				
	therapy ($N = 19$,				
	$N_{female} = 9; M_{age} =$				
	$14.7 \pm 2.4)$				
Ducharme et al.	One 16-years-old girl	Acceptability measure	No follow-up	Acceptability outcome	-Engagement issues of patients with
[74]	who disclosed	- Revised session		- Positive feedback on the intervention	anger problems in the intervention
Mightier	depression, suicidal	reaction scale		experience (e.g.,	- Difficulty to determine the
	ideation and thoughts of	Behavioral measure		enjoyment, helpfulness)	mechanisms that led to the
	hurting family members	- STAXI-CA		Behavioral/Report outcomes	intervention-related improvement
				- Decreased scores of State Anger and	- Unknown generalizability of the
				Trait Anger after the intervention	improvement to the contexts outside th
				- Considerable improvement in the	therapeutic settings
				ability to use emotional regulation skills	- The necessity of randomized clinical
					The needoonly of fundomined ennied

the intervention

(Continued)

- Plausible constraints (e.g., the

the intervention

necessity of managed care for more than five consecutive days) on the benefits of

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
Schoneveld et al.	Children showing	Acceptability and	3 months	Acceptability and feasibility outcomes	-The potential bias in report
(37)	elevated anxiety	feasibility measures		- No group difference in game	measurements
MindLight	symptoms ($N_{screened} =$	- Game expectations		expectations at the baseline	- The possibility of the contamination
	757, $N_{\text{finalsample}} = 136$,	- Game evaluations		- The evaluation of MindLight as a	between the groups due to the play
	$N_{female} = 73$; age range:	Behavioral measures		significantly more anxiety-inducing	context where both groups played in t
	$8-13$ years, $M_{age} = 9.95$	- SCAS-C/P		game compared to Max and the	same room
	± 1.33)	Additional measure		evaluation of Max as a significantly	- The exclusion of a passive control
	1. MindLight group	- Average weekly time		more appealing game compared	group
	$(N = 9, N_{dropout} = 1)$	for game playing		to MindLight	- The lack of the understanding about
	2. Control game (i.e.,			Behavioral outcomes	reasons for the improvement in
	"Max") group ($N =$			- Significantly lower mean scores on	children's anxiety symptoms
	$67, N_{dropout} = 1)$			total anxiety symptoms in the	
				MindLight group than in the control	
				game group at the post-test but	
				non-significant effect of game	
				conditions on anxiety outcome	
				measures	
				- No group difference in anxiety	
				symptoms at the follow-up; significant	
				decreases in levels of anxiety symptoms	
				in both groups over time	
Schoneveld et al.	Children showing	Acceptability and	3 months and 6 months	Acceptability and feasibility outcomes	- The plausible influence of the
(76)	elevated anxiety	feasibility measures		- The children's ratings of MindLight	information that was given to children
MindLight	symptoms ($N = 174$,	- Program expectations		and the CBT program as equally	and parents to equalize expectations
C	$N_{female} = 103$; age range:	before the group		appealing interventions across time	across the conditions on the results
	7–12 years, $M_{age} = 9.97$	allocation		points	- No available information about the
	±1.16)	- The evaluation of the		- The rating of the CBT program as	mechanisms of the effectiveness of
	1. MindLight group (N	program the		more relevant to daily lives	the interventions
	= 86, N _{finalsample} =	participants received		, than MindLight	
	72)	Behavioral measures		Behavioral outcomes	
	2. CBT group ($N = 88$,	- SCAS-C/P		- Significant decreases in anxiety	
	$N_{\text{finalsample}} = 72)$	Additional measure		symptoms over time and slowed rate of	
		- Average weekly time		the decrease over time	
		for game playing		- No sigfnicant group difference in	
		0 1 7 0		anxiety symptoms after the intervention	
				/ ·/ ··· r	

Choi et al.

10.3389/fpsyt.2022.986687

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
Wijnhoven et al.	Children and adolescents	Acceptability measure	3 months	Primary outcome	- Some concerns for drop-outs and late
(77)	with ASD who showed at	- PETS		- No significant group differences in	completion of assessments
MindLight	least subclinical level of	Primary outcome		child-rated anxiety symptoms after	- The weak original model fits due to th
	anxiety symptoms ($N =$	measure		the intervention	sample size despite the correction
	109; age range: 8-16	- SCAS-C		Secondary outcomes	- No available information for
	years, $M_{age} = 11.10$	Secondary outcome		- No significant group difference in	mechanisms that contributed to the
	± 2.07)	measures		parent-rated anxiety symptoms after the	improvement of anxiety symptoms
	1. MindLight group (N	- SCAS-P		intervention but significantly decreased	- Some concerns for the reliability of
	= 53)	- ADIS-P		parent-rated anxiety symptoms in the	SCAS-C in children with ASD
	2. Control game (i.e.,			MindLight group compared to the	- The interference of the research team
	"Triple Town") group			control game group at the follow-up	in the content of treatments that
	(N = 56)			- No group difference in remission rates	children received in parallel with
					MindLight or the control game, and th
					plausible effects of the treatment
					contents on anxiety symptoms
					- The usage of ADIS-P as the
					measurement for the remission rates of
					anxiety disorders but not as an indicate
					for changes in anxiety severity
Wijnhoven et al.	Children with ASD who	- Primary outcome	3 months	Primary outcome	- The difficulty to find a significant
(78)	showed at least	measure		- Clinically significantly decreased	additive effect of CBT due to the
MindLight	subclinical level of	- SCAS-C		anxiety symptoms in five participants	improvement of anxiety symptoms in
	anxiety symptoms ($N =$	Secondary outcome		during the MindLight intervention	some children during MindLight
	8, $N_{female} = 1$; Age range:	measures		Secondary outcomes	sessions
	8-12 years)	- SCAS-P		- Remission of some phobias (e.g., social	- The plausible subjectivity in the visua
		- ADIS-P		phobia) and/or generalized anxiety	analysis of data
		- CSLK		disorder in five children at the follow-up	
				compared to the baseline	
				- Significantly decreased avoidance in	

three children for more than one phases

- Significantly increased positive coping skills (e.g., direct problem solving) in

three children, mixed changes in positive coping skills in two children and significantly decreased positive coping skills in one children

of the study

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
Merry et al. (58)	Children and adolescents	Primary outcome	3 months	Acceptability and feasibility	-The insufficient power of the study to
SPARX	with mild to moderate	measure		- Low dropout rates in both groups	detect the superiority of SPARX over
	depressive disorder			- A good level of adherence in SPARX	treatment as usual
	$(N_{screened} = 213,$			group with the completion of at least	
	$N_{finalsample} = 187; age$			four modules of SPARX in 86%	
	range: 12-19 years)			participants	
	1. SPARX group ($N =$	-CDRS-R		- The report of 49 adverse events overall	- Logistic difficulty of adding more tha
	94, N _{dropout} = 9,	Secondary outcome		but mostly unrelated to the study	one measure on the interview due to
	$N_{female} = 59; M_{age} =$	measures		- The report of helpfulness and	various issues (e.g., the necessity of ext
	$15.55 \pm 1.54)$	- Reynolds adolescent		satisfaction regarding the interventions	time)
	2. Treatment as usual	depression scale-second		in the majority of both groups	- No exclusion of spontaneous
	group ($N = 93$,	edition		Primary outcomes	improvements in both group due to th
	$N_{dropout} = 8$, N_{female}	- mood and feelings		- Non-significant but greater reduction	study design
	$= 64; M_{age} = 15.58$	questionnaire		in mean scores of CDRS-R in the	- The heterogeneity of the treatment as
	± 1.66)	- pediatric quality of life		SPARX group compared to the	usual group
		enjoyment and		treatment as usual group	
		satisfaction		- Significantly higher remission rates on	
		questionnaire		the primary outcome in SPARX group	
		- Spence children's		than in treatment as usual group	
		anxiety scale		Secondary outcomes	
		- Kazdin hopelessness		- Significantly higher changes in mean	
		scale for children		scores of measures (i.e., Kazdin	
		1. CGI		hopelessness scale, mood and feelings	
				questionnaire and the Spence	
				generalized subscale) in the SPARX	
				group compared to the treatment as	
				usual group but no group difference in	
				the clinical global	
				impression-improvement response rate	
				- Maintained treatment effects in	
				SPARX G at 3-month follow-up	
Fleming et al. (79)	Adolescents with	Primary outcome	10 weeks	Acceptability outcome	Small sample size
SPARX	depressive symptoms in	measure		£ /	- Short follow-up period
	- / -				* *

10.3389/fpsyt.2022.986687

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	programs (N _{screened} =	- CDRS-R		-Report of six adverse events (i.e.,	- Post-intervention and follow-up
	49, $N_{finalsample} = 32$; age	Secondary outcome		increased depressive symptoms in four	assessments conducted by the research
	range: 13–16 years, M _{age}	measures		participants in the waitlist group and	who was not blinded
	$= 14.9 \pm 0.79$) 1. SPARX	- Reynold Adolescents		two self-harm incidents unrelated to	- No validation of used outcome
	group ($N = 20$)	Depression Scale		the intervention)	measures in this specific group
	2. Waitlist group (N	- Pediatric Quality of Life		Primary outcome	
	= 12)	Enjoyment and		- Significantly greater decreases in	
		Satisfaction		scores of CDRS in the SPARX group	
		Questionnaire		than in waitlist group immediately after	
		- Spence Anxiety Scale		the intervention	
		- Kazdin Hopelessness		- Non-significant changes in outcomes	
		Scale		between post-intervention and 10-week	
		- Children's		follow-up in the SPARX group	
		Nowicki-Strickland		Secondary outcomes	
		Internal-External		- Significantly greater decreases in	
		Control Scale short form		Reynold adolescents depression scale in	
				the SPARX group compared to the	
				waitlist group immediately after the	
				intervention but non-significant	
				changes in other secondary outcomes	
Poppelaars et al. (8)	Girls with elevated	Acceptability measure	3-, 6-, and 12-month	Acceptability outcome	-The limited genralizability of the
SPARX	depressive symptoms (N	- Evaluation of the			findings and the limited random
	= 208; age range: 11-16	program at post-test		-Similar level of satisfaction in OVK and	allocation of participants into each
	years, $M_{age} = 13.35$	Outcome measures		SPARX programs	group
	$\pm 0.71)$	- Reynolds adolescent		- The rating of OVK as a more attractive	- Small sample size for subgroups of
	1. OVK (i.e., a	Depression Scale		and useful intervention than SPARX	adolescents to be distinguished for the
	depression prevention	- Item 9 (i.e., suicidal		Outcomes	identification of a more effective
	program) group (N =	ideation) of CDI		- Significant decreases in depressive	program
	50)			symptoms over time from the screening	- The exclusion of male adolescents by
	2. SPARX group ($N =$			to the follow-up in all groups	focusing on female adolescents who
	51)				were at higher risk for depression

Choi et al.

Study & DTx	Participants	Measures	Follow-up	Results	Limitations
	3. OVK and SPARX			Similar rates of changes in depressive	-Unknown mechanisms for the change
	combined group			symptoms in all groups and similar level	resulted from the intervention
	(<i>N</i> = 56)			of depressive were at higher risk for	- Lack of understanding about the
	4. Monitoring control			depression symptoms in all groups at	effectiveness of each aspect of games in
	group ($N = 51$)			one-year follow-up	the context of interventions
				- The prediction of greater depressive	- The deviation of depression
				symptoms at the one-year follow-up	measurements used in the current stud
				from greater depressive symptoms at the	from other studies
				baseline	
				- No group difference in	
				suicidal ideation	
Lucassen et al. (69)	Children and adolescents	- Patient health	No follow-up	- Low completion rates (i.e., the	- The low completion rates
SPARX	(age range: 12-19 years)	questionnaire -modified		completion of Module 4 in less than 10%	- The restricted single sex/gender item
	1. Transgender	for adolescents		of participants and the completion of	in the used self-report (i.e., the limited
	adolescents ($N = 294$;			Module 7 in less than 4% of participants	effectiveness of the measurement for
	Age 12–15 = 131, Age			- Significantly improved scores of	transgender adolescents)
	16-19 = 76)			patient health questionnaire modified	
	2. Male adolescents			for adolescents in male and female	
	(<i>N</i> = 4,135; Age			adolescents after the intervention but no	
	12–15 = 1,927, Age			change in scores in	
	16-19 = 977)			transgender adolescents	
	3. Female adolescents				
	(<i>N</i> = 9,060; Age				
	12–15 = 3,595, Age				
	16-19 = 2,373)				

IA, inattention; TOVA, test of variables of attention; BRIEF, Behavior Rating Inventory of Executive Function; CANTAB, Cambridge Neuropsychological Test Automated Battery; API, Attention Performance Index; ADHD-RS, ADHD rating scale; SSIS, social skills improvement system; IRS, impairment rating scale; CGI-I, Clinical Global Impressions-improvement; BASM, BCI ADHD severity Measure; CBCL, Child Behavior Checklist; PERMP, Permanent Product Measure of Performance; WJ-III, Woodcock-Johnson Third Edition; SDQ, Strengths and Difficulties Questionnaire; ERICA, Emotion-Regulation Index for Children and Adolescents; EATQ-R, Early Adolescent Temperament Questionnaire ÜRevised; FD-CMS, Functional and Dysfunctional Child Mood Scales; TS-VAS, Treatment Satisfaction Visual Analogue Scales; CASI, Child and Adolescent Scale of Irrationality; CATS-N/P, Children's Automatic Thoughts Scale-Negative/Positive; PAD, Profile of Affective Disorder; SCAS-C/P, Spence Children's Anxiety Scale - child & parent versions; ADIS-P, Anxiety Disorders Interview Schedule for DSM-IV, Parent version; PETS, Parent Expectancies for Therapy Scale; CSLK, Coping Strategies Checklist for Children; STAXI-CA, State Anger, Trait Anger, Anger Expression-Out, Anger Expression-In & Anger Control; CDRS-R, Children's depression rating scale-revised; OVK, Op Volle Kracht. and adolescents were maintained for 3 months after the interventions (4, 20, 37, 58, 76, 77). The effectiveness of SPARX on depression was also maintained in children who were excluded from mainstream education at the 10-weeks follow-up (79). Moreover, the treatment effects of some DTx were maintained for longer durations. Larger decreases in anxiety symptoms that were reported by children who played MindLight were maintained at the 6-months follow-up and the sustained improvement in anxiety symptoms was reported by both children and their parents (76). Unlike the sustained improvement of anxiety symptoms in both children who played MindLight and those who played the control game, "Max", at the follow-up (37), not parents of children, who played the control game (i.e., "Triple Town"), but parents of children, who played MindLight, reported the sustained decreases in their anxiety symptoms at the follow-up (77). In case of EndeavorRx, its therapeutic effects on attention function in children with SPD and inattentive-ADHD were sustained for 9 months after the intervention (60). Furthermore, receiving three booster training sessions of ATENTIVmynd during the 3-months follow-up did not show the further improvement of attention function at the follow-up (4). That is, the therapeutic effect of ATENTIVmynd on attention function was maintained without the additional training sessions (4). However, the extent of improvement of anxiety symptoms was lesser in children who played MindLight and reported the highest weekly engagement time in gaming (76). Taken together, although the sustainability of RECOGNeyes, REThink, and Mighter was not examined, EndeavorRx, ATENTIVmynd, MindLight, and SPARX were found to show sustained therapeutic effects on targeted mental health problems (i.e., attention function, anxiety and depressive symptoms) for at least 3 months outside the intervention period.

The transfer of cognitive functions in DTx

When the extent to which cognitive functions were improved in game-based DTx was investigated, they showed the near transfer of cognitive functions. Both children with ADHD and typically developing children showed improvement in spatial working memory (WM) after playing EndeavorRx (42). However, the significant improvement in WM and inhibition after EndeavorRx intervention was found not in typically developing children but in children with ADHD (42). Despite the trend of improvement in WM in children with ADHD, children with a more severe level of ADHD showed the significant improvement in WM and inhibition (42). Children, who played REThink, and those, who received REBE intervention, also showed the significant improvement in focused attention (11). However, the extent of improvement of cognitive functions was limited to the characteristics of gamebased DTx. Children, who played ATENTIVmynd, showed

the improvement in focused attention by staying on tasks, completing more questions in the time limit and correctly answering more questions compared to those in the control group but did not show improvements in reading and math fluency after playing ATENTIVmynd (20). That is, DTx that targeted attention deficit or aimed to prevent emotional problems through the development of emotion regulation showed the improvement in cognitive functions that were related to the targeted mental health problems.

Discussion

This study aimed to review whether there are therapeutic effects of game-based DTx that are developed to target mental health problems in children and adolescents by delivering treatment or prevention interventions through VGs. It also reviewed whether the therapeutic effects of game-based DTx are sustainable and/or show the transfer of cognitive functions. Based on the review of literatures for the seven game-based DTx, it is found that using VGs as a delivery tool for treatment or prevention interventions in children and adolescents have the potential for therapeutic effects on targeted mental health problems (i.e., attention deficit, anxiety symptoms, emotion regulation and depression). The therapeutic effects of gamebased DTx on mental health problems for this age group are at least comparable to that of frequently used treatment interventions (e.g., CBT) or are greater than some of the treatment interventions (e.g., REBE intervention). Moreover, game-based DTx show the persistent therapeutic effect of mental health problems in children and adolescents in at least short term (e.g., 3 months) and the near transfer of cognitive functions.

Acceptability and feasibility

Implementing VGs in DTx that aim to treat or prevent mental health problems in children and adolescents appears to be acceptable and feasible. Among seven game-based DTx, EndeavorRx (42, 44, 57), ATRNTImynd (4), Mightier (66) and SPARX (58, 79) show a higher level of adherence to the interventions without the reports of serious adverse events that are related to the DTx intervention. The acceptability and feasibility of EndeavorRx are found in children with ADHD (42), children with ADHD and ASD (57) and children with SPD and inattentive symptoms (60). Mild adverse events (i.e., the frustration in 3% of children and the headache in 2% of the children) that were reported in EndeavorRx also do not result in the dropout of the study (44). In case of SPARX, although the lower adherence level of SPARX in the sample including transgender adolescents is found (69), the study that examined the feasibility and acceptability of SPARX in

adolescents in inpatient settings suggests that SPARX is a feasible intervention for adolescent patients with a greater severity of mental health problems (70). Moreover, the positive evaluation for EndeavorRx, Recogneyes, REThink, and SPARX (e.g., the enjoyment, satisfaction and helpfulness) is reported (11, 45, 57, 58, 63, 66, 74). In case of RECOGNeyes, age influences the evaluation of the intervention (63). While children, who were younger than 12 years, reported that RECOGNeyes were enjoyable and challenging without difficulty, those, who were older than 12 years, reported that RECOGNeyes were not interesting to play (63). Furthermore, unlike the suggested potential of VGs as an attractive and immersive tool to deliver clinical interventions in children and adolescents (33, 34), MindLight and SPARX are found to be rated as interventions that are less relevant with daily lives and less useful than CBT or CBT-based interventions despite the comparable appealing or satisfaction level (8, 76). These results suggest the necessity of further studies to examine factors that could influence the acceptability and feasibility of game-based DTx (e.g., age). Taken together, as EndeavorRx is the firstly approved DTx that delivers the treatment for children and adolescents through VGs (56), more studies for the acceptability and feasibility of game-based DTx should be conducted.

Immediate therapeutic effects

Despite the difference in the focus of DTx on the way to implement VGs, such as the focus on structural characteristics such as storylines [e.g., (37, 42)] and/or the controller to play VGs [e.g., (63, 66)], identified seven game-based DTx are found to be effective in treating or preventing targeted mental health problems in children and adolescents as standalone DTx [i.e., DTx that could treat targeted disorders independently (29, 80)]. It was because not only behavioral improvement in targeted mental health symptoms but also the alterations in symptom-relevant brain regions are found. Consistent with the potential of digital interventions for the cognitive rehabilitation (32), EndeavorRx (60, 71), ATENTIVmynd (72), and REThink (24) show alterations in brain regions that are associated with the behavioral improvement. However, in case of MindLight, although the extent of improvement of anxiety symptoms through MindLight intervention does not significantly differ from the improvement of anxiety through control commercial games (37, 77), MindLight appears to be an effective intervention to improve anxiety symptoms in children by offering a more anxiety-inducing environment where children could learn and practice emotion regulation strategies in response to triggered anxiety (37). The burdens of time investment, one of the reasons for dropping out of CBT program, are also not reported in MindLight (76). Moreover, the therapeutic or preventive effects of game-based DTx on targeted mental health problems are greater in children who report more

severe levels of mental health problems than in those with less severe mental health problems (4, 42, 58, 60, 77). That is, children and adolescents, who are more likely to fail in receiving frequently used treatments or to report lower remission rates [e.g., children with SPD (60) and children with ASD in addition to ADHD (57)], show the improvement of targeted mental health problems after playing game-based DTx. These results suggest that DTx offer more personalized intervention environments where children and adolescents could experience the optimal level of challenge for their mental health problems (36, 37), resulting in the successful intervention results for those who show limited therapeutic effects through frequently used treatments (37, 41). Furthermore, the therapeutic effects of EndeavorRx and Mightier are found in children without attention deficits (42, 60) and those whose primary mental health problem is not the difficulty to control anger (66). Taken together, game-based DTx are suggested to show therapeutic or preventive effects on mental health problems by overcoming limitations of frequently used interventions. The DTx are also suggested to have the potential to not only be applied to children with mental health conditions that are relevant with targeted mental health problems but also improve cognitive functions in the general population of children and adolescents.

Although delivering treatment or prevention interventions for targeted mental health problems through VGs in DTx enables more personalized interventions for children and adolescents, personal factors (e.g., gender) seem to have the potential influence on the therapeutic effects of DTx. In SPARX, the extent to which hopelessness decreases and the quality of life improves is different between different groups of children and adolescents. Unlike the improvement in these aspects in children with mild to moderate level of depression (58), adolescents, who were excluded from mainstream education, did not report significant reduction in their hopelessness and improvement in life quality after playing SPARX (79). Moreover, unlike male and female adolescents, transgender adolescents also did not show the improvement in depressive symptoms through SPARX intervention (69). The potential influence of personal factors on the therapeutic effects of DTx could hinder the objective understanding for the effectiveness of game-based DTx in targeted mental health problems or could provide useful information for designing game-based DTx in the future. Thus, further studies should be conducted.

The sustainability of therapeutic effects

Consistent with the potential that the implementation of VGs have for the generalization of learned skills (37), the improvement in targeted mental health problems (i.e., attention deficit, anxiety and depression) in children and adolescents are found to be sustained for more than 10 weeks after the interventions (4, 20, 37, 58, 60, 76, 77, 79). In case of MindLight,

children showed greater improvement of anxiety symptoms than those, who received CBT, not at the 3-month follow-up but at the 6-month follow-up (76). That is, game-based DTx appear to have to potential to overcome the limited sustainable therapeutic effects of frequently used treatments outside the intervention period. The sustained therapeutic effects of DTx on mental health problems suggest the generalization of acquired knowledge or skills into daily lives (41) in that not only children but also their parents or clinicians report the improvement of targeted mental health problems (4, 37, 58, 76, 77). Moreover, as receiving additional training sessions of ATENTIVmynd outside the intervention period did not result in further improvement of attention function in children (4), offering the appropriate level of game-based DTx interventions is found to be sufficient to persistently improve targeted mental health problems in children and adolescents. However, the lesser extent of the sustained improvement in anxiety symptoms is found in children who played MindLight and reported the highest amount of gaming time per week (76). As the commercial game with structural characteristics that are similar to MindLight (e.g., controlling the avatar and requiring the overcoming of fear) show the sustained improvement of anxiety symptom at the follow-up (37), it seems that some structural characteristics of commercial VGs could help the improvement of anxiety symptoms or interfere with the sustainability of therapeutic effects of game-based DTx. In order to understand the interference between commercial game playing and gamebased DTx, further studies examining the influence of structural characteristics of VGs on therapeutic effects of DTx should be conducted. Furthermore, gaming behavior is identified as one of factors that could influence the maintenance of therapeutic effects of DTx. The change and maintenance of anxiety symptoms through MindLight is found to be predicted by gaming behavior of children (68). While avoidant/safety behaviors predicted increased anxiety symptoms 3 months after the training, engaged gaming behaviors predicted the reduction in anxiety (68). That is, for the better understanding about the sustainability of game-based DTx, further studies should be conducted by investigating the types of engagement behavior and other plausible factors that could influence the sustainability of DTx.

Cognitive improvements

Along with alterations in brain activations related to targeted mental health problems of EndeavorRx, ATENTIVmynd and REThink [e.g., inhibited activation in right frontal brain regions (24), increased MFT activity power (60), and reorganized functional networks (72)], cognitive functions that are relevant with targeted mental health problems (e.g., spatial WM, inhibition and focused attention) are found to show the improvement in children after playing EndeavorRx,

ATENTIVmynd, or REThink (11, 20, 42). However, despite the relevance of the focused attention with academic performance, playing ATENTIVmynd does not result in the improvement in academic performance (e.g., reading) (20). That is, consistent with the near transfer of cognitive improvements that was found in VG playing (54), game-based DTx show the near transfer effects for the cognitive improvement. Moreover, although the improvement in spatial WM and inhibition were found in children with and without attention deficits after playing EndeavorRx, those, who reported more severe levels of attention deficit, showed the significant improvement in related cognitive functions along with the greater immediate therapeutic effects of EndeavorRx (42). That is, game-based DTx seem to booster therapeutic effects by improving not only targeted mental health problems but also relevant cognitive functions in children who have more difficulties to learn targeted skills in frequently used treatments. Further studies should be conducted to examine whether the extent of therapeutic effects of DTx in children with more severe mental health problems is modulated by the improvement of relevant cognitive functions.

Limitations

Although both immediate and sustainable therapeutic effects of game-based DTx on targeted mental health problems in children and adolescents are found, four limitations are identified in this review. The first limitation is that the therapeutic effects of DTx are based on relatively small sample size. While more than 100 participants were included in some studies [e.g., (24, 37, 44, 58)], other studies in this review examined the therapeutic effects of DTx based on relatively small sample size. For example, the effectiveness of Mightier in the improvement of emotion regulation in children and adolescents was based on the study included 37 children (66) and one case study (74). As the results of the therapeutic effects of DTx based on small sample size showed the limited generalization of the findings (38), further studies with larger sample sizes should be conducted.

The second limitation is that the motivation of game playing and structural characteristics of VGs are not sufficiently considered. In order to ensure the therapeutic effects of MindLight on anxiety symptoms in children by controlling attention, motivation, behavioral activation and expectations (37, 81), commercial games were used as active control conditions (37, 77). However, game playing itself appears to provide children with the environment where they could train their anxiety reduction-related skills (e.g., resilience and self-efficacy) (35) and it is found that children, who report clinical level of mental health problems, are more likely to play games for the reduction of stress (82). As the motivation of game playing makes it difficult to understand the therapeutic effects of MindLight on anxiety, including additional control groups should be considered in future studies. Moreover, there are inconsistencies in the sustainability of improved anxiety between studies. While children, who played the commercial game, showed sustained improvement of anxiety at the follow-up like those who played MindLight (37), playing commercial games for longer time was found to decrease the extent of sustainability of therapeutic effects of MindLight (76). Thus, further studies that would explore the structural characteristics of VGs that could influence the immediate and/or sustained therapeutic effects of game-based DTx should be conducted.

The third limitation is that self-report measurements that ask children to explicitly indicate their suggestive states (83) are frequently used to examine therapeutic effects of game-based DTx in most studies. The explicit indication of subjective states could be challenging for them in that metacognitive insights are required (83). Although reports are also completed by their parents or clinicians in some studies [e.g., (58, 77)], physiological measurements (e.g., EEG) that are less sensitive to cognitive factors that could bias self-reports could offer more objective information (24) especially in studies where the blinding of conditions is limited. Among included research articles, only four studies [e.g., (24, 60)] are found to include the physiological measurements. As structural and functional alterations in brain regions were influenced by various experiences (e.g., physical activity and cognitive training) (84), investigating the alterations in brain regions after playing game-based DTx would provide valuable and objective information about their effectiveness in addition to behavioral evidence. That is, further studies that include physiological measurements should be conducted.

The last limitation is that the number of studies that examine the extent to which DTx are sustainable in shortterm and long-term or show the transfer of cognitive functions is limited. Based on the short-term and long-term followups for the investigation of the sustainability of game-based DTx, they are found to overcome the limited sustainability of frequently used treatments. However, most studies focus on the short-term maintenance of treatment effectiveness and the therapeutic or preventive effects of some DTx are not followed up. As the sustainability of the effectiveness of DTx outside the intervention period is one of important concerns that are reported in mental health interventions (43, 44), more studies that would follow up the therapeutic effects of DTx in long-terms should be conducted. Moreover, greater therapeutic effects of game-based DTx in children with more severe level of mental health problems and the significant improvement in cognitive functions that are related to targeted mental health problems (42) suggest the potential of cognitive remediation through game-based DTx that could result in greater therapeutic effects. Despite the potential of game-based DTx in cognitive remediation (32), only three studies that were included in this review [e.g., (46)] are found to examine the transfer of cognitive functions in game-based DTx. In order to ensure that game-based DTx show sustainable therapeutic effects and have additional effects on VG-related cognitive improvement, studies that would follow up the sustainability of therapeutic effects of DT in longer terms and that would investigate the extent of cognitive improvement after playing game-based DTx should be conducted in the future.

Conclusion

Game-based DTx that aims to treat or prevent targeted mental health problems in children and adolescents are found to be acceptable and feasible. They are also found to show therapeutic or preventive effects on attention function, emotional regulation, anxiety symptom and depression. The therapeutic effects of game-based DTx are sustained in at least short term outside the intervention period. Cognitive functions that are related to the targeted mental health problems also show the improvement. However, there are factors that have the potential to influence the therapeutic effects of DTx or the sustainability of therapeutic effects. Moreover, there are limitations that should be considered in understanding the evidence for the therapeutic effects of DTx. In order to investigate the therapeutic effects of game-based DTx in children and adolescents more objectively, studies that consider the identified factors and limitations should be conducted in the future.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

EC, EY, and MP contributed to data collection, literature review, and the writing of the manuscript. EC was a major contributor in writing the manuscript. MP contributed to the planning, analysis, and supervision of the study. All authors have read and approved the final manuscript.

Funding

This work was supported by the Technology Innovation Program (or Industrial Strategic Technology Development Program) (PC20ONDI0074, AI Driven Global PHR Pediatric Developmental Disability Management/Treatment Platform) funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea) and by National Research Foundation of Korea (NRF) grant funded by the Korean Government (NRF-2020R1F1A1070581). The funders did not have any role in study design, literature review, decision to publish, and preparation of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA, et al. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. *J Child Psychol Psychiatry.* (2015) 56:345–65. doi: 10.1111/jcpp.12381

2. Elsabbagh M, Divan G, Koh Y-J, Kim YS, Kauchali S, Marcin C, et al. Global prevalence of autism and other pervasive developmental disorders. *Autism Res.* (2012) 5:160–79. doi: 10.1002/aur.239

3. Collishaw S. Annual research review: secular trends in child and adolescent mental health. *J Child Psychol Psychiatry.* (2015) 56:370–93. doi: 10.1111/jcpp.12372

4. Lim CG, Lee TS, Guan C, Fung DSS, Zhao Y, Teng SSW, et al. A brain-computer interface based attention training program for treating attention deficit hyperactivity disorder. *PLoS ONE.* (2012) 7:e46692. doi: 10.1371/journal.pone.0046692

5. Kim-Cohen J, Caspi A, Moffitt TE, Harrington H, Milne BJ, Poulton R, et al. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. *Arch Gen Psychiatry.* (2003) 60:709–17. doi: 10.1001/archpsyc.60.7.709

6. Aldao A, Nolen-Hoeksema S, Schweizer S. Emotion-regulation strategies across psychopathology: a meta-analytic review. *Clin Psychol Rev.* (2010) 30:217–37. doi: 10.1016/j.cpr.2009.11.004

7. MCLaughlin KA, Hatzenbuehler ML, Mennin DS, Nolen-Hoesksema S. Emotion dysregulation and adolescent psychopathology: a prospective study. *Behav Res Ther.* (2011) 49:544–54. doi: 10.1016/j.brat.2011.06.003

8. Poppelaars M, Tak YR, Lichtwarck-Aschoff A, Engels RCME, Lobel A, Merry SN, et al. A randomized controlled trial comparing two cognitive-behavioral programs for adolescent girls with subclinical depression: a school-based program (Op Volle Kracht) and a computerized program (SPARX). *Behav Res Therapy.* (2016) 80:33–42. doi: 10.1016/j.brat.2016.03.005

9. Birmaher B, Williamson DE, Dahl RE, Axelson DA, Kaufman J, Dorn LD, et al. Clinical presentation and course of depression in youth: does onset in childhood differ from onset in adolescence? J Am Acad Child Adolesc Psychiatry. (2004) 43:63–70. doi: 10.1097/00004583-200401000-00015

10. Costello J, Mustillo S, Erkanli A, Keeeler G, Angold A. Prevalence and development of psychiatric disorders in childhood and adolescence. *Arch Gen Psychiatry.* (2003) 60:837–44. doi: 10.1001/archpsyc.60.8.837

11. David OA, Cardoş RA, Matu S. Is REThink therapeutic game effective in preventing emotional disorders in children and adolescents? Outcomes of a randomized clinical trial. *Eur Child Adolesc Psychiatry.* (2019) 28:111–22. doi: 10.1007/s00787-018-1192-2

12. Patulny R, Muir K, Powell S, Flaxman S, Oprea I. Are we reaching them yet? Service access patterns among attendees at the headspace youth mental health initiative. *Child Adolesc Ment Health.* (2013) 18:95–102. doi: 10.1111/j.1475-3588.2012.00662.x

13. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. *Neuropsychol Rev.* (2007) 17:61–72. doi: 10.1007/s11065-006-9017-3

14. Buitelaar J. Optimising treatment strategies for ADHD in adolescence to minimise 'lost in transition' to adulthood. *Epidemiol Psychiatr Sci.* (2017) 26:448–52. doi: 10.1017/S2045796017000154

15. Toomey SL, Sox CM, Rusinak D, Finkelstein JA. Why do children with ADHD discontinue their medication? *Clin Pediatr.* (2012) 51:763-9. doi: 10.1177/0009922812446744

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

16. Thapar A, Collishaw S, Pine DS, Thapar AK. Depression in adolescence. Lancet. (2012) 379:1056-67. doi: 10.1016/S0140-6736(11)60871-4

17. Olfson M, Blanco C, Wang S, Laje G, Correll CU. National trends in the mental health care of children, adolescents, and adults by office-based physicians. *JAMA Psychiatry*. (2014) 71:81–90. doi: 10.1001/jamapsychiatry.2013.3074

18. Coates J, Taylor JA, Sayal K. Parenting interventions for ADHD: a systematic literature review and meta-analysis. J Atten Disord. (2015) 19:831–43. doi: 10.1177/1087054714535952

19. Schnyder N, Sawyer MG, Lawrence D, Panczak R, Burgess P, Harris MG, et al. Barriers to mental health care for Australian children and adolescents in 1998 and 2013–2014. *Aus New Zealand J Psychiatry.* (2020) 54:1007–19. doi: 10.1177/0004867420919158

20. McDermott AF, Rose M, Norris T, Gordon E. A novel feed-forward modeling system leads to sustained improvements in attention and academic performance. *J Atten Disord.* (2020) 24:1443–56. doi: 10.1177/1087054715623044

21. Simkin DR, Thatcher RW, Lubar J. Quantitative EEG and neurofeedback in children and adolescents: anxiety disorders, depressive disorders, comorbid addiction and attention-deficit/hyperactivity disorder, and brain injury. *Child Adolesc Psychiatr Clin.* (2014) 23:427–64. doi: 10.1016/j.chc.2014.03.001

22. Butnik SM. Neurofeedback in adolescents and adults with attention deficit hyperactivity disorder. J Clin Psychol. (2005) 61:621–5. doi: 10.1002/jclp.20124

23. Kola L. Global mental health and COVID-19. Lancet Psychiatry. (2020) 7:655-7. doi: 10.1016/S2215-0366(20)30235-2

24. David OA, Predatu R, Maffei A. REThink online video game for children and adolescents: effects on state anxiety and frontal alpha asymmetry. *Int J Cogn Therapy*. (2021) 14:388–416. doi: 10.1007/s41811-020-00077-4

25. Hollis C, Morriss R, Martin J, Amani S, Cotton R, DenisM, et al. Technological innovations in mental healthcare: harnessing the digital revolution. *Br J Psychiatry.* (2015) 206:263–5. doi: 10.1192/bjp.bp.113.142612

26. Dang A, Arora D, Rane P. Role of digital therapeutics and the changing future of healthcare. *J Family Med Primary Care.* (2020) 9:2207. doi: 10.4103/jfmpc.jfmpc_105_20

27. Bhavnani SP, Narula J, Sengupta PP. Mobile technology and the digitization of healthcare. *Eur Heart J.* (2016) 37:1428–38. doi: 10.1093/eurheartj/ehv770

28. Dallery J, Kurti A, Erb P. A new frontier: integrating behavioral and digital technology to promote health behavior. *Behav Analyst.* (2015) 38:19-49. doi: 10.1007/s40614-014-0017-y

29. An S. The Trend of Digital Therapeutics, in BIO ECONOMY BRIEF. KoreaBIO: Korea Bio-Economy Research Center. (2020)

30. Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. *NPJ Digital Med.* (2020) 3:159. doi: 10.1038/s41746-020-00370-8

31. Recchia G, Capuano MR, Mistri N, Verna R. Digital therapeuticswhat they are, what they will be. *Acta Sci Med Sci.* (2020) 4:1-9. doi: 10.31080/ASMS.2020.04.0575

32. Abbadessa G, BrigoF, Clerico M, Mercanti SD, Trojsi F, Tedeschi G, et al. Digital therapeutics in neurology. *J Neurol.* (2022) 269:1209–24. doi: 10.1007/s00415-021-10608-4

33. Craven MP, Groom MJ. Computer games for user engagement in Attention Deficit Hyperactivity Disorder (ADHD) monitoring and therapy. in 2015. *Int Conf Interactive Technol Games.* (2015). IEEE:34–40. doi: 10.1109/iTAG.2015.9 34. Shah A, Kraemer KR, Won CR, Black S, Hasenbein W. Developing digital intervention games for mental disorders: a review. *Games Health J.* (2018) 7:213–24. doi: 10.1089/g4h.2017.0150

35. Granic I, Lobel A, Engels RC. The benefits of playing video games. Am Psychol. (2014) 69:66. doi: 10.1037/a0034857

36. Barnes S, Prescott J. Empirical evidence for the outcomes of therapeutic video games for adolescents with anxiety disorders: systematic review. *JMIR Serious Games*. (2018) 6:e3. doi: 10.2196/games.9530

37. Schoneveld EA, Malmberg M, Lichtwarck-Aschoff A, Verheijen GP, Engels RCME, Granic I, et al. A neurofeedback video game (MindLight) to prevent anxiety in children: a randomized controlled trial. Comp Human Behav. (2016) 63:321–33. doi: 10.1016/j.chb.2016.05.005

38. Cardo R, Predatu R, David O. Development and validation of a cartoon based set of children's facial emotion stimuli for the REThink online therapeutic game. *Cog Behav Coach.* (2016) 39–43.

39. Fisak BJ, Richard D, Mann A. The prevention of child and adolescent anxiety: a meta-analytic review. *Prev Sci.* (2011) 12:255–68. doi: 10.1007/s11121-011-0210-0

40. Kazdin AE. Evidence-based treatment research: advances, limitations, and next steps. *Am Psychol.* (2011) 66:685. doi: 10.1037/a0024975

41. Zayeni D, Raynaud J-P, Revet A. Therapeutic and preventive use of video games in child and adolescent psychiatry: a systematic review. *Front Psychiatry.* (2020) 11:36. doi: 10.3389/fpsyt.2020.00036

42. Davis NO, Bower J, Kollins SH. Proof-of-concept study of an athome, engaging, digital intervention for pediatric ADHD. *PLoS ONE.* (2018) 13:e0189749. doi: 10.1371/journal.pone.0189749

43. Weiss M, Childress A, Mattingly G, Nordbrock E, Kupper RJ, Adjei AL, et al. Relationship between symptomatic and functional improvement and remission in a treatment response to stimulant trial. *J Child Adolesc Psychopharmacol.* (2018) 28:521–9. doi: 10.1089/cap.2017.0166

44. Kollins SH, DeLoss DJ, Canadas E, Lutz J, Findling PRL, Keefe RL, et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. *Lancet Digital Health.* (2020) 2:e168–78. doi: 10.1016/S2589-7500(20)30017-0

45. Kahn J, Ducharme P, Rotenberg A, Gonzalez-Heydrich J. "RAGEcontrol": a game to build emotional strength. *Games Health J.* (2013) 2:53– 7. doi: 10.1089/g4h.2013.0007

46. Colder Carras M, Van Rooji AJ, Spruijt-Metz D, Kvedar J, Griffiths MD, Carabas Y, et al. Commercial video games as therapy: a new research agenda to unlock the potential of a global pastime. *Front Psychiatry.* (2018) 8:300. doi: 10.3389/fpsyt.2017.00300

47. Hollis C, Falconer CJ, Martin JL, Whittington C, Stockton S, Glazebrook C, et al. Annual research review: digital health interventions for children and young people with mental health problems–a systematic and meta-review. *J Child Psychol Psychiatry Invest.* (2017) 58:474–503. doi: 10.1111/jcpp.12663

48. Wiederhold BK. Data-driven digital therapeutics: the path forward. *Cyberpsychol Behav Soc Netw.* (2021) 24:631–2. doi: 10.1089/cyber.2021.29227.editorial

49. Phirom K, Kamnardsiri T, Sungkarat S. Beneficial effects of interactive physical-cognitive game-based training on fall risk and cognitive performance of older adults. *Int J Env Res Public Health.* (2020) 17:6079. doi: 10.3390/ijerph17176079

50. Pichierri G, Murer K, de Bruin ED. A cognitive-motor intervention using a dance video game to enhance foot placement accuracy and gait under dual task conditions in older adults: a randomized controlled trial. *BMC Geriatr.* (2012) 12:1–14. doi: 10.1186/1471-2318-12-74

51. Wang G, Zhao M, Yang F, Cheng LJ, Lau Y. Game-based brain training for improving cognitive function in community-dwelling older adults: a systematic review and meta-regression. *Arch Gerontol Geriatr.* (2021) 92:104260. doi: 10.1016/j.archger.2020.104260

52. Toril P, Reales JM, Mayas J, Ballesteros S. Video game training enhances visuospatial working memory and episodic memory in older adults. *Front Human Neurosci.* (2016) 10:206. doi: 10.3389/fnhum.2016.00206

53. Anguera JA, Boccanfuso J, Rintoul JL, Al-Hashimi O, Faraji F, Janowich J, et al. Video game training enhances cognitive control in older adults. *Nature*. (2013) 501:97–101. doi: 10.1038/nature12486

54. Choi E, Shin S-H, Ryu J-K, Jung K-I, Kim S-Y, Park M-H, et al. Commercial video games and cognitive functions: video game genres and modulating factors of cognitive enhancement. *Behav Brain Funct.* (2020) 16:1–14. doi: 10.1186/s12993-020-0165-z

55. Oei AC, Patterson MD. Are videogame training gains specific or general? *Front Syst Neurosci.* (2014) 8:54. doi: 10.3389/fnsys. 2014.00054

56. Akili_Interactive_Labs. Akili Announces FDA Clearance of EndeavorRxTM for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game. (2020). Available online at: https://www.akiliinteractive.com/news-collection/akili-announces-endeavortm-attention-treatment-is-now-available-for-children-with-attention-deficit-hyperactivity-disorder-adhd-al3pw (accessed December 22, 2020).

57. Yerys BE, Bertollo JR, Kenworthy L, Dawson G, Marco EJ, Schultz RT, et al. Brief report: pilot study of a novel interactive digital treatment to improve cognitive control in children with autism spectrum disorder and co-occurring ADHD symptoms. *J Autism Develop Disord.* (2019) 49:1727-37. doi: 10.1007/s10803-018-3856-7

58. Merry SN, Stasiak K, Shepherd M, Frampton C, Fleming T, Lucassen MFG, et al. The effectiveness of SPARX, a computerised self help intervention for adolescents seeking help for depression: randomised controlled non-inferiority trial. *BMJ.* (2012) 344:e2598. doi: 10.1136/bmj.e2598

59. David OA, Predatu RM, Cardoş RA-I. A pilot study of the REThink online video game applied for coaching emotional understanding in children and adolescents in the therapeutic video game environment: the feeling better resources game. J Evid-Based Psychotherap. (2018) 18:57–67. doi: 10.24193/jebp.2018.1.5

60. Anguera JA, Brandes-Aitken AN, Antovich AD, Rolle CE, Desia SS, Marco EJ, et al. A pilot study to determine the feasibility of enhancing cognitive abilities in children with sensory processing dysfunction. *PLoS ONE.* (2017) 12:e0172616. doi: 10.1371/journal.pone.0172616

61. FDA, De Novo Classification Request For EndeavorRx. (2020)

62. ATENTIVHealth. *Products that Teach the Exective Fucntion Skills of Attention*. Available online at: https://www.atentiv.com/products.html (accessed December 22, 2020).

63. García-Baos A, D'Amelio T, Oliveira I, Collins P, Echevarria C, Zapata LP, et al. Novel interactive eye-tracking game for training attention in children with attention-deficit/hyperactivity disorder. *Prim Care Companion CNS Disord*. (2019) 21:26348. doi: 10.4088/PCC.19m02428

64. Mightier. Available online at: https://www.mightier.com/science/ (accessed December 27, 2020).

65. Kahn J, Ducharme P, Travers B, Gonzalez-Heydrich J. RAGE control: regulate and gain emotional control. *Strat Future Health.* (2009) 3:335.

66. Ducharme P, Wharff EA, Kahn J, Hutchinson E, Logan G, Waber D, et al. Augmenting anger control therapy with a videogame requiring emotional control: a pilot study on an inpatient psychiatric unit. *Adolesc Psychiatry.* (2012) 2:323–32. doi: 10.2174/2210676611202040323

67. Wijnhoven LA, Creemers DHM, Engels RCM, Granic I. The effect of the video game Mindlight on anxiety symptoms in children with an Autism Spectrum Disorder. *BMC Psychiatry*. (2015) 15:1–9. doi: 10.1186/s12888-015-0522-x

68. Wols A, Lichtwarck-Aschoff A, Schoneveld EA, Granic I. In-game play behaviours during an applied video game for anxiety prevention predict successful intervention outcomes. *J Psychopathol Behav Assess.* (2018) 40:655– 68. doi: 10.1007/s10862-018-9684-4

69. Lucassen MF, Stasiak K, Fleming T, Frampton C, Perry Y, Shepherd M, et al. Computerized cognitive behavioural therapy for gender minority adolescents: Analysis of the real-world implementation of SPARX in New Zealand. *Aust New Zealand J Psychiatry.* (2021) 55:874–82. doi: 10.1177/0004867420976846

70. Bobier C, Stasiak K, Mountford H, Merry S, Moor S. Examination of the utility of a self-help computerised cognitive behavioural therapy (cCBT) program (SPARX) in an acute adolescent inpatient unit. *Adv Mental Health.* (2013) 11:286–92. doi: 10.5172/jamh.2013.11.3.286

71. Gallen CL, Anguera JA, Gerdes MR, Simon AJ, Canadas E, Marco EJ, et al. Enhancing neural markers of attention in children with ADHD using a digital therapeutic. *PLoS ONE.* (2021) 16:e0261981. doi: 10.1371/journal.pone.0261981

72. Qian X, Loo BRY, Castellanos FX, Liu S, Koh HL, Poh XWW, et al. Brain-computer-interface-based intervention re-normalizes brain functional network topology in children with attention deficit/hyperactivity disorder. *Transl Psychiatry.* (2018) 8:1–11. doi: 10.1038/s41398-018-0213-8

73. David OA, Cardos RA, Matu S. Changes in irrational beliefs are responsible for the efficacy of the REThink therapeutic game in preventing emotional disorders in children and adolescents: mechanisms of change analysis of a randomized clinical trial. *Euro Child Adoles Psych.* (2019) 28:307-18. doi: 10.1007/s00787-846018-1195-z

74. Ducharme P, Wharff E, Hutchinson E, Kahn J, Logan G, Gonzalez-Heydrich J. Videogame assisted emotional regulation training: an ACT with RAGE-Control case illustration. *Clin Soc Work J.* (2012) 40:75–84. doi: 10.1007/s10615-011-0363-0

75. Sukhodolsky DG. Randomized trial of anger control training for adolescents with Tourette's syndrome and disruptive behavior. J Am Acad Child Adolesc Psychiatry. (2009) 48:413–21. doi: 10.1097/CHI.0b013e3181985050

76. Schoneveld EA, Lichtwarck-Aschoff A, Granic I. Preventing childhood anxiety disorders: is an applied game as effective as a cognitive behavioral therapy-based program? *Prev Sci.* (2018) 19:220–32. doi: 10.1007/s11121-017-0843-8

77. Wijnhoven LA, Creemers DHM, Vermulst AA, Lindauer RJL, Otten R, Engels RCME, et al. Effects of the video game 'Mindlight'on anxiety of children with an autism spectrum disorder: a randomized controlled trial. *J Behav Therapy Exp Psychiatry.* (2020) 68:101548. doi: 10.1016/j.jbtep.2020.101548

78. Wijnhoven LA, Engels RCME, Onghena P, Otten R, Creemers DHM. The additive effect of CBT elements on the video game 'mindlight'in decreasing anxiety symptoms of children with autism spectrum disorder. *J Autism Develop Disord.* (2022) 52:150–68. doi: 10.1007/s10803-021-04927-8

79. Fleming T, Dixon R, Frampton C, Merry S, et al. A pragmatic randomized controlled trial of computerized CBT (SPARX) for symptoms of depression among adolescents excluded from mainstream education. *Behav Cogn Psychother*. (2012) 40:529–41. doi: 10.1017/S1352465811000695

80. GlobalData. Digital Therapeutics (DTx) and their Impact on Healthcare. (2019). GlobalData.

81. Boot WR, Simons DJ, Stothart C, Stutts C. The pervasive problem with placebos in psychology: why active control groups are not sufficient to rule out placebo effects. *Perpect Psychol Sci.* (2013) 8:445–54. doi: 10.1177/1745691613491271

82. Ferguson CJ, Olson CK. Friends, fun, frustration child for video game play. 10.1007/s11031and fantasy: motivations (2013) Motivat Ėmot. 37:154-64. doi: 012-9284-7

83. Deighton J, Croudace T, Fonagy P, Brown J, Patalay P, Wolpert M. Measuring mental health and wellbeing outcomes for children and adolescents to inform practice and policy: a review of child self-report measures. *Child Adolesc Psychiatry Mental Health.* (2014) 8:1–14. doi: 10.1186/1753-2000-8-14

84. Ballesteros S, Kraft E, Santana S, Tziraki C, et al. Maintaining older brain functionality: a targeted review. *Neurosci Biobehav Rev.* (2015) 55:453–77. doi: 10.1016/j.neubiorev. 2015.06.008